

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):	Seymour Fein	GROUP NUMBER:	1614
		CONFIRMATION NO.:	7710
APPLICATION NO:	10/706,100	EXAMINER:	Tate
FILING DATE:	November 12, 2003		
TITLE:	PHARMACEUTICAL COMPOSITIONS INCLUDING LOW DOSAGES OF DESMOPRESSIN		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO OFFICE ACTION

Sir:

This communication is responsive to the Office action mailed October 16, 2007, in the above-mentioned application. Applicant encloses a Petition for Extension of Time under 37 C.F.R. § 1.136(a) extending the deadline for response by three months up to and including April 16, 2008. Applicant authorizes the Office to charge the associated fees, and any other fees required for the entry and consideration of this paper, to Deposit Account No. 07-1700 (Ref. No. SER-001).

In response to the Office action mailed October 16, 2007, Applicant submits the following amendments and remarks.

This paper is responsive to a substitute office action received after an interview conducted on September 11, 2007, with Examiners Kosar, Tsang and Tate; Applicant's attorney Edmund Pitcher; Dr. Seymour Fein, the inventor of the subject matter of this application; and Dr. Samuel Herschkowitz, the CEO of Serenity Pharmaceuticals, exclusive licensee of the subject

matter of this application. The substance of the interview was set forth in an interview summary prepared by the undersigned and submitted to the office on September 18, 2007.

Applicant also thanks Examiner Kosar for the telephonic interview conducted with Edmund Pitcher on October 23, 2007. In that interview, Examiner Kosar clarified language in the Office action of October 16, 2007. Specifically, Examiner Kosar indicated that the word “misrepresents” in the Office action should have been “misinterprets,” as the Office action was merely questioning Applicant’s interpretation of the prior art.

Please amend the above-identified patent application as follows:

Amendments to the Claims begin on page 3 of this paper.

Amendments to the Drawings are discussed on page 5 of this paper.

Remarks begin on page 6 of this paper.